Artificial Intelligence
Earendil Labs
A Delaware-incorporated, Beijing-headquartered biotech applying machine learning across the entire biologics R&D process, from antibody discovery through development and manufacturing. Earendil raised $787 million in March 2026, backed by Sanofi and the Pfizer/Hillhouse Biotech Development Fund alongside Dimension Capital, DST Global Partners, and Luminous Ventures; its AI-native platform has produced more than 40 programs including HXN-1001, a half-life extended anti-TL1A antibody ready for Phase 2 development, and it holds two major Sanofi licensing deals worth up to $1.72 billion and $2.56 billion in milestones for bispecific antibodies targeting autoimmune diseases.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
2 sources · 63% avg. source confidence
- BioSpace / PR Newswire — Earendil Labs raises $787M for AI-driven biologics discovery and development66% source confidence
- PR Newswire — Earendil Labs' two Sanofi licensing deals worth up to $4.28B in combined milestones60% source confidence
Dependency Map
What Earendil Labs depends on below, and who depends on Earendil Labs above — click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Earendil Labs's Timeline
A sourced, dated history of Earendil Labs's key moments — founding to present.
Apr 2025 · First Sanofi licensing deal for bispecific antibodies
Sanofi paid $125 million upfront (with up to $1.72 billion in milestones) for exclusive global rights to two Earendil-designed bispecific antibodies targeting autoimmune and IBD indications.
Jan 2026 · Second Sanofi deal for additional autoimmune programs
Sanofi arranged a second deal with Earendil worth up to $160 million upfront and $2.56 billion in milestones for additional autoimmune programs from Earendil's AI-native platform.
Mar 2026 · Raises $787M to scale AI-driven biologics platform
Earendil Labs raised $787 million in financing, backed by Sanofi and the Pfizer/Hillhouse Biotech Development Fund alongside Dimension Capital, DST Global Partners, and Luminous Ventures, to scale its AI-native biologics discovery and development platform.